From Wikipedia, the free encyclopedia - View original article

  (Redirected from NeuroAid)
Jump to: navigation, search

Neuroaid (also NeuroAiD, MLC 601, or MLC 901) is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. There are two versions: Neuroaid (MLC601) and Neuroaid II (MLC901), with differing blends of ingredients.[1] The ingredients total 14 for both, with nine derived from plants and five from animals.[2]

Mechanisms of action[edit]

In vitro and in vivo results show that Neuroaid makes cells more resistant against glutamate aggression, increases neurite outgrowth and connectivity as well as reduces the infarct volume.[1]


There is weak evidence that Neuroaid (MLC 601) might have some benefit for post-stroke recovery when used in addition to standard treatment.[3]


  1. ^ a b Heurteaux C, Gandin C, Borsotto M, et al. (June 2010). "Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo". Neuropharmacology 58 (7): 987–1001. doi:10.1016/j.neuropharm.2010.01.001. PMID 20064536. 
  2. ^ Broussalis E, Trinka E, Killer M, Harrer A, McCoy M, Kraus J (2012). "Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies". Drug Discov Today 17 (13-14): 671–84. doi:10.1016/j.drudis.2012.02.011. PMID 22405898. 
  3. ^ Siddiqui, Fahad Javaid; Venketasubramanian, Narayanaswamy; Chan, Edwin Shih-Yen; Chen, Christopher (2013). "Efficacy and Safety of MLC601 (NeuroAiD®), a Traditional Chinese Medicine, in Poststroke Recovery: A Systematic Review". Cerebrovascular Diseases 35: 8–17. doi:10.1159/000346231. PMID 23548914.